January 8, 2019 07:56 AM EST

Billed as potential blockbuster, Novartis' sickle cell drug scores FDA's breakthrough therapy status

Touted by Novartis chief Vas Narasimhan as a potential blockbuster, the Swiss drugmaker’s sickle cell disease (SCD) drug has secured the FDA’s

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Billed as po­ten­tial block­buster, No­var­tis' sick­le cell drug scores FDA's break­through ther­a­py sta­tus